1. Home
  2. PHUN vs SNTI Comparison

PHUN vs SNTI Comparison

Compare PHUN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phunware Inc.

PHUN

Phunware Inc.

N/A

Current Price

$2.08

Market Cap

39.3M

Sector

Technology

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

N/A

Current Price

$1.04

Market Cap

31.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PHUN
SNTI
Founded
2009
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.3M
31.5M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
PHUN
SNTI
Price
$2.08
$1.04
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$7.25
$8.50
AVG Volume (30 Days)
89.4K
156.1K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
39.36
77.31
EPS
N/A
N/A
Revenue
$30,883,000.00
N/A
Revenue This Year
$89.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.57
N/A
52 Week Low
$1.56
$0.77
52 Week High
$3.70
$2.88

Technical Indicators

Market Signals
Indicator
PHUN
SNTI
Relative Strength Index (RSI) 53.83 51.78
Support Level $1.79 $1.02
Resistance Level $2.11 $1.04
Average True Range (ATR) 0.07 0.07
MACD 0.01 -0.00
Stochastic Oscillator 68.88 47.89

Price Performance

Historical Comparison
PHUN
SNTI

About PHUN Phunware Inc.

Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services. Development services for customers who wish to have a customized application experience; and In-app advertising services for mobile audience building, user acquisition, application discovery, audience engagement and monetization.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: